ITM’s ITM-11 Receives the FTD by the US FDA for the Treatment of Neuroendocrine Tumors
Shots:
- The company received an FTD from the US FDA for ITM-11 to treat gastroenteropancreatic neuroendocrine tumors currently being evaluated in the P-III (COMPETE) & (COMPOSE) study
- The P-III (COMPETE) & (COMPOSE) trials evaluate the safety & efficacy of ITM-11 vs standard therapy in patients (n=309 & 202) with inoperable, progressive, grade 1 & 2 (COMPETE) & grade 2 & 3 (COMPOSE) SSTR+ neuroendocrine tumors of GEP-NETs. The 1EPs of the study includes PFS & the 2EPs includes OS
- ITM-11 is a therapeutic radiopharmaceutical comprised of a medical radioisotope n.c.a. 177Lu & the targeting molecule edotreotide which is a synthetic form of the peptide hormone somatostatin targeting the neuroendocrine tumor-specific receptors
Ref: GlobeNewswire | Image: ITM
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
